Upexi（7TQ0）株式概要ブランド・オーナーであるUpexi, Inc.は、ペット、外科、回復、皮膚、美容、健康、ウェルネス市場における消費者向け製品の開発、製造、販売に従事している。 詳細7TQ0 ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長1/6過去の実績0/6財務の健全性0/6配当金0/6報酬収益は年間15.1%増加すると予測されています リスク分析キャッシュランウェイが1年未満である マイナスの株主資本 過去5年間で収益は年間62%減少しました。 German市場と比較して、過去 3 か月間の株価の変動が非常に大きい+2 さらなるリスクすべてのリスクチェックを見る7TQ0 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€1.16275.0% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-228m66m2016201920222025202620282031Revenue US$52.8mEarnings US$5.1mAdvancedSet Fair ValueView all narrativesUpexi, Inc. 競合他社BeiersdorfSymbol: XTRA:BEIMarket cap: €15.9bNumans Health Food HoldingsSymbol: SEHK:2530Market cap: HK$650.0mVenture Life GroupSymbol: AIM:VLGMarket cap: UK£68.8mSkinHealth SystemsSymbol: NasdaqCM:SKINMarket cap: US$89.1m価格と性能株価の高値、安値、推移の概要Upexi過去の株価現在の株価US$1.1652週高値US$8.6052週安値US$0.46ベータ-0.291ヶ月の変化-0.086%3ヶ月変化151.62%1年変化n/a3年間の変化-98.01%5年間の変化n/aIPOからの変化-98.86%最新ニュースBoard Change • May 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gene Salkind was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 06+ 1 more updateUpexi, Inc., Annual General Meeting, Jun 15, 2026Upexi, Inc., Annual General Meeting, Jun 15, 2026. Location: at 3030 n. rocky point drive, suite 420, fl 33607, tampa United Statesお知らせ • Feb 10Upexi, Inc. has completed a Follow-on Equity Offering in the amount of $7.41429 million.Upexi, Inc. has completed a Follow-on Equity Offering in the amount of $7.41429 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,337,000 Price\Range: $1.17 Discount Per Security: $0.0585 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 6,337,000 Transaction Features: Registered Direct Offeringお知らせ • Feb 06Upexi, Inc. has filed a Follow-on Equity Offering.Upexi, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,337,000 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 6,337,000 Transaction Features: Registered Direct Offeringお知らせ • Feb 05Upexi, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.Upexi, Inc. has filed a Follow-on Equity Offering in the amount of $500 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Jan 31Upexi, Inc. to Report Q2, 2026 Results on Feb 10, 2026Upexi, Inc. announced that they will report Q2, 2026 results on Feb 10, 2026最新情報をもっと見るRecent updatesBoard Change • May 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gene Salkind was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 06+ 1 more updateUpexi, Inc., Annual General Meeting, Jun 15, 2026Upexi, Inc., Annual General Meeting, Jun 15, 2026. Location: at 3030 n. rocky point drive, suite 420, fl 33607, tampa United Statesお知らせ • Feb 10Upexi, Inc. has completed a Follow-on Equity Offering in the amount of $7.41429 million.Upexi, Inc. has completed a Follow-on Equity Offering in the amount of $7.41429 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,337,000 Price\Range: $1.17 Discount Per Security: $0.0585 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 6,337,000 Transaction Features: Registered Direct Offeringお知らせ • Feb 06Upexi, Inc. has filed a Follow-on Equity Offering.Upexi, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,337,000 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 6,337,000 Transaction Features: Registered Direct Offeringお知らせ • Feb 05Upexi, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.Upexi, Inc. has filed a Follow-on Equity Offering in the amount of $500 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offeringお知らせ • Jan 31Upexi, Inc. to Report Q2, 2026 Results on Feb 10, 2026Upexi, Inc. announced that they will report Q2, 2026 results on Feb 10, 2026お知らせ • Dec 02Upexi, Inc. announced that it has received $10.000001 million in fundingOn December 2, 2025, Upexi, Inc. announced that it has received $ 10,000,000 in funding from issuance of common stock of the company and closed the transaction. The company raised $10,000,000 upfront with up to an additional $ 13,000,000 of aggregate gross proceeds upon the cash exercise in full of warrants of the company which adds up to $ 23,000,000 in proceeds.お知らせ • Nov 26Upexi, Inc. announced that it expects to receive $10.000001 million in fundingUpexi, Inc. announced that it has entered into a securities purchase agreement with a single institutional investor for issuance of 3,289,474 common shares at a price of $3.04 per share for gross proceeds of $10,000,000.96; and warrants to purchase up to 3,289,474 common shares on November 26, 2025. The warrants will have an exercise price of $4, will be immediately exercisable, and will expire 48 months from issuance. The closing of the offering is expected to occur on or about December 1, 2025, subject to the satisfaction of customary closing conditions.お知らせ • Nov 14Upexi, Inc. (NasdaqCM:UPXI) announces an Equity Buyback for $50 million worth of its shares.Upexi, Inc. (NasdaqCM:UPXI) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of it's shares.お知らせ • Nov 08Upexi, Inc. to Report Q1, 2026 Results on Nov 11, 2025Upexi, Inc. announced that they will report Q1, 2026 results on Nov 11, 2025お知らせ • Oct 24Upexi, Inc. Welcomes Jon Najarian to the Upexi Advisory CommitteeUpexi, Inc. announced the addition of Jon Najarian to the Upexi Advisory Committee, joining Arthur Hayes and S?L Big Brain as founding Upexi Advisory Committee members. Jon Najarian is a highly influential figure in the world of finance, renowned for his deep expertise in options trading and market strategy. A former professional football player, Jon co-founded options trading firm Mercury Trading and later launched financial education company Market Rebellion, cementing his reputation as a market heavyweight across both professional and retail trading. He is an inductee into the U.S. Options Industry Council Hall of Fame, having received the Lifetime Contribution Award in recognition of his enduring impact on the industry. Beyond his trading acumen, Jon is a prominent media personality, frequently appearing on Fox Business, NewsMax, NewsNation, and other financial platforms, where his market analyses and actionable insights reach millions of investors. With a combination of professional credibility, entrepreneurial success, and exceptional visibility, Jon has emerged as one of the most recognized and trusted voices for both institutional and retail traders navigating complex markets.お知らせ • Aug 12Upexi, Inc. Announces Establishment of Advisory CommitteeUpexi, Inc. announced the establishment of the Upexi Advisory Committee, composed of highly prominent individuals from the digital assets and traditional finance industries. Upexi will seek to leverage the expertise, visibility and network of the Advisory Committee by: In conjunction with the establishment of the Advisory Committee, Upexi has welcomed Arthur Hayes (Twitter: @CryptoHayes) as its first member. A former equity derivatives trader at Deutsche Bank and Citigroup, Arthur’s deep financial acumen and bold vision quickly propelled him to the forefront of the digital assets space, where he co-founded BitMEX, one of the world’s largest cryptocurrency exchanges, and revolutionized digital asset trading with the invention of the perpetual swap – the most widely-traded crypto financial product of all time. Arthur is widely regarded as a thought leader whose market insights and macroeconomic commentary are followed closely by investors around the world. His fearless approach to innovation and profound impact on the industry has cemented his legacy as one of the space’s most iconic and respected voices. Additional Advisory Committee members will be announced over the coming weeks, with Committee-related content and initiatives forthcoming over the coming year and beyond. Arthur Hayes is the CIO of Maelstrom, a family office that invests across the crypto ecosystem. He is also the co-founder of BitMEX – the first crypto unicorn. Prior to entering the crypto industry, he worked as a trader in the capital markets divisions of Deutsche Bank and Citibank. Arthur holds a Bachelors of Economics from the Wharton School of Business. He has appeared on major business news networks including Bloomberg and CNBC. He is active on X (@cryptohayes) and releases a monthly newsletter (Crypto Trader Digest) read by thousands of investors globally.お知らせ • Jul 26Upexi, Inc. announced that it expects to receive $500 million in funding from A.G.P. / Alliance Global Partners Corp.Upexi, Inc announced a private placement and entered into a purchase agreement with A.G.P./Alliance Global Partners to issue common shares for aggregate gross proceeds of $500,000,000 on July 25, 2025. Pursuant to the purchase agreement, the Company shall have the right, but not the obligation, to direct the Investor to purchase the lesser of (i) $500,000,000 or (ii) the Exchange Cap, which shall be the number of shares not to exceed 19.99% of the Company’s shares of common stock, par value $0.00001 per share, outstanding on July 25, 2025, unless the Company’s stockholders have approved the issuance of Common Stock in excess of the Exchange Cap, upon satisfaction of certain terms and conditions contained in the Purchase Agreement, including, but not limited to, an effective registration statement filed with the U.S. Securities and Exchange Commission. The Common Stock will be offered pursuant to the exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) of Regulation D promulgated thereunder, and applicable state securities laws.お知らせ • Jul 17Upexi, Inc. announced that it has received $199.828744 million in funding from Big Brain HoldingsOn July 17, 2025, Upexi, Inc closed the transaction. The company issued convertible Notes for aggregate gross proceeds of $150,000,000 in its second and final tranche. The transaction included participation from from Big brain Holdings as a lead Investor among other Institutional Investors and qualified purchasers.お知らせ • Jul 13Upexi, Inc. announced that it expects to receive $49.828744 million in fundingUpexi, Inc. announces that it has entered into securities purchase agreements to issue 12,457,186 shares of common stock at a price of $4 per share for gross proceeds of $49,828,744 on July 11, 2025. The closing of the Equity Offering is expected to occur on or about July 14, 2025.お知らせ • May 17Upexi, Inc. announced delayed 10-Q filingOn 05/16/2025, Upexi, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 01Upexi, Inc., Annual General Meeting, Jun 16, 2025Upexi, Inc., Annual General Meeting, Jun 16, 2025. Location: 3030 n. rocky point drive, suite 420, florida 33607., tampa, United Statesお知らせ • Apr 26Upexi, Inc. announced that it has received $99.99211 million in funding from GSR, Big Brain, White Star Capital, L.P., Delta Blockchain Fund LPOn April 24, 2025, Upexi, Inc. closed the transaction. The company issued 35,970,383 shares of common stock and 7,889,266 pre-funded warrants at a price of $2.28 per share for aggregate gross proceeds of approximately $100 million.お知らせ • Apr 21Upexi, Inc. announced that it expects to receive $100 million in funding from GSR, Big Brain, White Star Capital, L.P., Delta Blockchain Fund LP and other investorsUpexi, Inc. announced that it has entered into securities purchase agreements with certain investors to issue 43,859,649 shares of common stock or pre-funded warrants at issue price of $2.28 per share for gross proceeds of $99,999,999.72 on April 21, 2025. The transaction includes participation from lead investor, GSR Markets UK Limited, Big Brain, Anagram, Delphi Ventures, White Star Capital, Maelstrom, the family office of Arthur Hayes, Hivemind, Borderless, Morgan Creek, Elune Capital, and Delta Blockchain Fund, including Austin Federa, Frank Chaparro, Joey Krug, Bartosz Lipinski, Larry Wu, and Jordan Prince, among others including Allan Marshall. The closing of the offering is expected to occur on or about April 24, 2025. The offer and sale of the foregoing securities is being made in a private placement in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended and/or Regulation D promulgated thereunder, or applicable state securities laws.お知らせ • Nov 22Upexi Receives Notice from the Nasdaq Stock MarketUpexi, Inc. received a Non Compliance Letter from The Nasdaq Stock Market LLC due to the Company’s failure to timely file its Form 10-Q Quarterly Report for the period ended September 30, 2024, in violation of Nasdaq Listing Rule 5250(c)(1). The Company failed to timely file due to circumstances beyond its control, and intends to file its Form 10-Q Quarterly Report shortly after it is able to file its Form 10-K Annual Report. Pursuant to the Nasdaq Listing Rules, the Company has until December 20, 2024 to submit a plan to regain compliance. If the plan is accepted, an extension may be granted of up to 180 calendar days from the due date of the Initial Delinquent Filing, or April 14, 2025, to regain compliance. The Notice has no immediate effect on the listing or trading of the Company’s common stock.お知らせ • Nov 15Upexi, Inc. announced delayed 10-Q filingOn 11/14/2024, Upexi, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 24+ 1 more updateUpexi, Inc. to Report Fiscal Year 2024 Results on Nov 01, 2024Upexi, Inc. announced that they will report fiscal year 2024 results at 9:30 AM, US Eastern Standard Time on Nov 01, 2024お知らせ • Oct 03Nasdaq Grants Additional 180 Days to Upexi to Regain Compliance with Minimum Bid Price RequirementUpexi, Inc. received a letter from The Nasdaq Stock Market LLC (Nasdaq") indicating that, for thirty consecutive business days prior to the date thereof, the bid price for the Company's common stock (the Common Stock") had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until September 30, 2024, to regain compliance. The Common Stock did not regain compliance with the Minimum Bid Price Requirement within such period. The Company timely requested, and was granted by Nasdaq on October 1, 2024, an additional 180 calendar days to regain compliance with the Minimum Bid Price Requirement.お知らせ • Oct 01Upexi, Inc. announced delayed annual 10-K filingOn 09/30/2024, Upexi, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.Board Change • Aug 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gene Salkind was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Aug 07David Romano, Nick Romano and Eric Limont acquired E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) for $2 million.David Romano, Nick Romano and Eric Limont acquired E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) for $2 million on August 1, 2024. A cash consideration of $2 million will be paid by E-Core Holdings, LLC. The purchase price in the transaction was $2 million. In addition, in connection with the closing of the transaction (i) Upexi, Inc. was released as a guarantor from E-Core, Inc’s commercial loan facility, and (ii) all subordinated promissory notes issued by Upexi, Inc. in connection with the Upexi, Inc.’s initial acquisition of E-Core, Inc were cancelled and any outstanding principal and interest thereunder was deemed paid in full. On the Closing Date, (a) each Transaction Document shall be deemed null and void, and all obligations of the parties thereunder shall terminate; (b) Upexi Newco shall assign and transfer back to Upexi Newcos all of E-Core Newco’s right, title and interest in and to 4,000 shares of common stock of E-Core purchased from Upexi Newco in the Transaction (the “ E-Core Shares ”), constituting all of E-Core’s issued and outstanding securities, free and clear of any liens or encumbrances; and (c) the Consideration shall be paid in full by the Parties. Dickinson Wright PLLC acted as legal advisor to Upexi, Inc. and Korn & Kalish LLP acted as legal advisor to David Romano, Nick Romano and Eric Limont. David Romano, Nick Romano and Eric Limont completed the acquisition of E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) on August 1, 2024.お知らせ • Jun 22Upexi Provides Update on Filing Form 10Q for March 31, 2024Upexi, Inc. (the Company" or Upexi") is providing shareholders with a update on filing its financial statements for the three and nine months ended March 31, 2024. On June 17, 2024, the Company received a notice from Nasdaq Listing Qualifications that since the Company has not yet filed its Form 10-Q for the period ended March 31, 2024 (the Filing"), it no longer complies with our Listing Rules (the Rules") for continued listing. Under the Rules the Company now has 60 calendar days to submit a plan to regain compliance and if we accept your plan, we can grant an exception of up to 180 calendar days from the Filing's due date, or until December 11, 2024, to regain compliance. Upexi management has discussed this with the Nasdaq and expects to file the form 10-Q for the period ended March 31, 2024 prior to the end of June 30, 2024 and once this is filed, a plan will not be necessary to regain compliance. The Nasdaq Notice Letter has no immediate effect on the listing or trading of the Company's common stock.お知らせ • Jun 21Upexi, Inc. to Report Q3, 2024 Results on Jun 24, 2024Upexi, Inc. announced that they will report Q3, 2024 results on Jun 24, 2024お知らせ • Jun 18MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC acquired VitaMedica Corporation from Upexi, Inc. (NasdaqCM:UPXI) for $6 million.MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC acquired VitaMedica Corporation from Upexi, Inc. (NasdaqCM:UPXI) for $6 million on June 13, 2024. A cash consideration of $4 million will be paid by MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC. MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC will pay an earnout/contingent payment of $1 million promissory note and of $1 million cash. As part of consideration, $6 million is paid towards common equity of VitaMedica Corporation. MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC acquired VitaMedica Corporation from Upexi, Inc. (NasdaqCM:UPXI) for $6 million on June 13, 2024.お知らせ • May 17Upexi, Inc. announced delayed 10-Q filingOn 05/15/2024, Upexi, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 03Upexi, Inc., Annual General Meeting, Jun 10, 2024Upexi, Inc., Annual General Meeting, Jun 10, 2024, at 09:00 US Eastern Standard Time. Location: 3030 N. Rocky Point Drive, Suite 420 Tampa United States Agenda: To elect five (5) director nominees, nominated by the board of directors, for a one-year term; to ratify the appointment of b f Borgers CPA pc as independent registered public accounting firm for the fiscal year ending June 30, 2024; and to consider such other business.New Risk • Apr 18New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.30m (US$9.92m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.0m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Market cap is less than US$10m (€9.30m market cap, or US$9.92m). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$5.6m net loss next year). Shareholders have been diluted in the past year (16% increase in shares outstanding).お知らせ • Apr 03Upexi Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)On April 1, 2024, Upexi, Inc. (the ‘Company’) received a letter (the ‘Nasdaq Bid Price Letter’) from The Nasdaq Stock Market LLC (‘Nasdaq’) indicating that, for thirty consecutive business days prior to the date thereof, the bid price for the Company’s common stock (the ‘Common Stock’) had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the ‘Minimum Bid Price Requirement’). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until September 30, 2024, to regain compliance (the ‘Compliance Period’). As of the date of this report, the Common Stock has not regained compliance with the Minimum Bid Price Requirement. In the event the Company does not regain compliance within the Compliance Period, the Company may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of the Company’s intention to cure the deficiency during said second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to Nasdaq that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Common Stock will be subject to delisting. The Nasdaq Bid Price Letter has no immediate effect on the listing or trading of the Common Stock. The Company intends to continue actively monitoring the bid price for its shares of Common Stock between now and the expiration of the Compliance Period and will consider all available options to resolve the deficiency including a reverse stock split, if necessary, with every intention to regain compliance with the Minimum Bid Price Requirement. In the event the Company receives notification from Nasdaq that the Common Stock is subject to delisting, the Company may appeal the Nasdaq staff’s determination before the Nasdaq Hearings Panel (the ‘Panel’). However, there can be no assurance that, in the event of such appeal, the Panel would grant the Company’s request for continued listing.Reported Earnings • Feb 15Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.17 profit in 2Q 2023)Second quarter 2024 results: US$0.12 loss per share (down from US$0.17 profit in 2Q 2023). Revenue: US$21.8m (down 19% from 2Q 2023). Net loss: US$2.44m (down 182% from profit in 2Q 2023). Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 5.4% growth forecast for the Personal Products industry in Europe.Board Change • Feb 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gene Salkind was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 15+ 1 more updateUpexi, Inc. Revises Preliminary and Unaudited Financial Guidance for the First Quarter Ended September 30, 2023Upexi, Inc. revised preliminary and unaudited financial guidance for the first quarter ended September 30, 2023. For the year, the company expects Revenue of approximately $27.3 million, an increase of 136% year-over-year and 53.2% sequentially, and above the previously issue revenue guidance range of $26 million to $27 million.お知らせ • Sep 15Upexi, Inc. Pet Care Brand, Luckytail, Announces Expansion of Product Line to Include All-Natural Dog SupplementsUpexi Inc. announced LuckyTail, its pet brand and leading designer and manufacturer of pet care solutions, is expanding its latest product line with the launch of all-natural dog supplements. The supplement line will be offered via subscription and in batches, delivering the most value for pet owners' health and grooming needs. The line includes six functional formulas to address the most common concerns dog owners have including, hip & joint, calming, flea & tick, probiotic and allergy & immune issues. With a focus on quality ingredients, all chews are all-natural, human-grade, GMP certified, third-party tested and made in the USA. The line features the following all-natural, chewable supplements: Calming chews improve emotional balance, support relaxation, and relieve stress and anxiety for dogs, a perfect complement to LuckyTail's Ultimate Nail Grinder. AllerImmune chews provide immune-boosting properties and relief from common dog allergy symptoms, including decreased paw licking, itching, flea & tick, and skin irritation. Flea & tick chews are an all-natural, chemical-free solution to help prevent pesky pests.ip & Joint chews promote healthier bones and joints, increased mobility, and reduce soreness and discomfort. As dogs age, their hips and joints can cause pain and discomfort. Probiotic chews provide a safe and effective way to improve pet gut health and reduce bloating, from immune support to gut and digestive health. Skin & Coat chews give dogs a beautiful shiny coat and healthy skin. These dog coat supplements help relieve itching, improve moisturizer, and boost immunity. This launch marks the first of many product expansions LuckyTail has planned, as the brand solidifies its position as a top source to connect pet parents with their pet care needs.お知らせ • Sep 08Amplifyir Inc. acquired 100% stake in Interactive Offers LLC from Upexi, Inc. (NasdaqCM:UPXI) for $1.25 million.Amplifyir Inc. entered into an equity interest purchase agreement to acquire 100% stake in Interactive Offers LLC from Upexi, Inc. (NasdaqCM:UPXI) for $1.25 million on August 31, 2023. In addition, there is an obligation to pay Upexi 2.5% of certain advertising revenues of Interactive for a two-year period post-closing. Peter Campitiello of McCarter & English acted as legal advisor to Interactive Offers LLC. Ross Carmel of Carmel, Milazzo & Feil LLP acted as legal advisor to Amplifyir.Amplifyir Inc. completed the acquisition of 100% stake in Interactive Offers LLC from Upexi, Inc. (NasdaqCM:UPXI) on August 31, 2023.New Risk • Aug 07New major risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (€39.5m market cap, or US$43.5m).お知らせ • May 19Upexi, Inc., Annual General Meeting, Jun 26, 2023Upexi, Inc., Annual General Meeting, Jun 26, 2023, at 10:00 Eastern Daylight. Location: 17129 US Hwy 19 N Clearwater Florida United States Agenda: To elect five (5) director nominees, nominated by the board of directors, for a one-year term, such term to continue until the annual meeting of shareholders in 2024 or until such director's successors are duly elected and qualified or until their earlier resignation or removal; to ratify the appointment of b f Borgers CPA pc as independent registered public accounting firm for the fiscal year ending June 30, 2023; and to consider such other business.Reported Earnings • May 16Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.003 loss in 3Q 2022)Third quarter 2023 results: US$0.11 loss per share (further deteriorated from US$0.003 loss in 3Q 2022). Revenue: US$24.2m (up 136% from 3Q 2022). Net loss: US$1.93m (loss widened US$1.88m from 3Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe.お知らせ • Feb 16Upexi, Inc. announced delayed 10-Q filingOn 02/15/2023, Upexi, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.Reported Earnings • Feb 16Second quarter 2023 earnings released: EPS: US$0.17 (vs US$0.004 in 2Q 2022)Second quarter 2023 results: EPS: US$0.17 (up from US$0.004 in 2Q 2022). Revenue: US$27.1m (up 154% from 2Q 2022). Net income: US$2.96m (up US$2.90m from 2Q 2022). Profit margin: 11% (up from 0.6% in 2Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 5.0% growth forecast for the Personal Products industry in Europe.Recent Insider Transactions • Dec 06CEO, President & Chairman of the Board recently bought €70k worth of stockOn the 1st of December, Allan Marshall bought around 18k shares on-market at roughly €3.77 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Allan's only on-market trade for the last 12 months.Reported Earnings • Nov 17First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.033 profit in 1Q 2022)First quarter 2023 results: US$0.15 loss per share (down from US$0.033 profit in 1Q 2022). Revenue: US$11.6m (up 37% from 1Q 2022). Net loss: US$2.55m (down US$3.06m from profit in 1Q 2022). Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 5.7% growth forecast for the Personal Products industry in Europe.Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. CEO, President & Chairman of the Board Allan Marshall is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 03Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of E-Core, Inc.Grove, Inc. (NasdaqCM:GRVI) signed a non-binding Letter of Intent to acquire E-Core, Inc on August 2, 2022. E- Core was acquired through Upexi. Grove plans to fund this acquisition without an additional equity offering. Grove and E-Core anticipate that the transaction will close in August 2022. Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of E-Core, Inc on November 2, 202. Upexi Inc. will pay consideration in combination of cash, stock and one-to-three year notes.お知らせ • Oct 28+ 1 more updateBloomios, Inc. (OTCPK:BLMS) acquired Infusionz, LLC from Upexi, Inc. (NasdaqCM:UPXI) for $23.5 million.Bloomios, Inc. (OTCPK:BLMS) acquired Infusionz, LLC from Upexi, Inc. (NasdaqCM:UPXI) for $23.5 million on October 27, 2022. The total purchase consideration of approximately $23.5 million consisted of cash consideration of $5.5 million and $18 million of non-cash consideration. The non-cash consideration consisted of the issuance by Bloomios to Upexi of a $4.5 million senior secured convertible debenture, a $5 million secured subordinated promissory note, and shares of a newly created Series D Convertible Preferred Stock with a value of $8.5 million. The acquisition was funded in part through a senior secured convertible debenture offering with an aggregate principal amount of approximately $13,893,059 (including a 15% original issue discount) led by institutional investors. The total new investment received in connection with the senior secured convertible debenture offering was $6.25 million with the balance of the principal amount consisting of issuances to Upexi and the refinancing of previous loans. Revere Securities LLC and Spartan Capital Securities, LLC acted financial advisors to Bloomios, Inc. Bloomios, Inc. (OTCPK:BLMS) completed the acquisition of Infusionz, LLC from Upexi, Inc. (NasdaqCM:UPXI) on October 27, 2022.お知らせ • Oct 12Upexi, Inc. Files Patent for its Single Click-to-optin TechnologyUpexi Inc. announced that its SaaS Ad Tech Division, Interactive Offers, has filed a patent for its single click-to-optin technology that has fueled growth and partnerships with large publishers. The competitive landscape and higher advertising costs have forced companies to lower budgets and/or try and find new opportunities. Interactive Offers' unique technology adds value for companies by changing the way advertisers pay for leads. With this new single click-to-optin technology, advertisers will no longer be paying per click or per impression, but will be bidding on a verified lead that has opted in to receive promotions and emails for each advertiser(s).お知らせ • Sep 30Upexi, Inc. Provides Revenue Guidance for the Fiscal Year 2023Upexi, Inc. provided revenue guidance for the Fiscal year 2023. For the period, the company estimates baseline annual revenue to be in the range of $72 to $82 million for the full fiscal year.Reported Earnings • Sep 29Full year 2022 earnings released: US$0.13 loss per share (vs US$0.25 profit in FY 2021)Full year 2022 results: US$0.13 loss per share (down from US$0.25 profit in FY 2021). Revenue: US$44.6m (up 85% from FY 2021). Net loss: US$2.10m (down 172% from profit in FY 2021). Revenue is forecast to grow 46% p.a. on average during the next 2 years, compared to a 5.6% growth forecast for the Personal Products industry in Europe.お知らせ • Sep 01Upexi, Inc. Appoints Anthony Bazan as Chief Operating OfficerOn August 29, 2022, Upexi, Inc. appointed Anthony Bazan as Chief Operating Officer of the Company. Mr. Bazan, age 57, joined the Company in August of 2022 as the Chief Operations Officer. Prior to joining the Company Mr. Bazan was CEO and Director of OnlineTech Stores and Group CEO and Director for Imaging Supplies Consolidation II, a Blackford Capital portfolio group. Mr. Bazan has a 30 year career in operations starting at Rockwell International, Easton Sports, Fiskars, Black & Decker, Jakks Pacific, Mega Brands, and TM International. At Mega Brands, Mr. Bazan was COO from 2008 to 2011. During his tenure Mega Brands grew $200 million in revenue and increased share price from $0.45 to $9.75. At TM International, Mr. Bazan served as CEO and Director from 2017 to 2021. During this period, Mr. Bazan was able to turn around a failing promotional products and e-commerce company, even during the height of COVID-19 when no promotional events were taking place. Mr. Bazan attended the Air Force Academy after earning both a Congressional and Senatorial nomination. A spinal injury caused him to depart the AFA early and honorably, while earning a Certificate of Completion in Engineering. Mr. Bazan continued his education gaining a BA in Economics from California State University of Northridge.Valuation Update With 7 Day Price Move • Aug 18Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to €4.66, the stock trades at a trailing P/E ratio of 24.2x. Average forward P/E is 25x in the Personal Products industry in Europe. Total loss to shareholders of 18% over the past year.お知らせ • Aug 03Grove, Inc. (NasdaqCM:GRVI) signed a non-binding LOI to acquire E-Core, Inc.Grove, Inc. (NasdaqCM:GRVI) signed a non-binding LOI to acquire E-Core, Inc on August 2, 2022. E- Core was acquired through Upexi. Grove plans to fund this acquisition without an additional equity offering. The deal uses debt, restricted equity, and payouts in subsequent years based on revenue and EBITDA milestones. Grove and E-Core anticipate that the transaction will close in August 2022.Valuation Update With 7 Day Price Move • Aug 02Investor sentiment improved over the past weekAfter last week's 18% share price gain to €4.86, the stock trades at a trailing P/E ratio of 26.6x. Average forward P/E is 27x in the Personal Products industry in Europe. Total returns to shareholders of 14% over the past year.Valuation Update With 7 Day Price Move • Jul 12Investor sentiment improved over the past weekAfter last week's 21% share price gain to €4.51, the stock trades at a trailing P/E ratio of 23.3x. Average forward P/E is 27x in the Personal Products industry in Europe. Negligible returns to shareholders over past year.お知らせ • Jun 26Grove, Inc.(NasdaqCM:GRVI) dropped from Russell Microcap Value IndexGrove, Inc.(NasdaqCM:GRVI) dropped from Russell Microcap Value IndexValuation Update With 7 Day Price Move • Jun 14Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €3.92, the stock trades at a trailing P/E ratio of 21.7x. Average forward P/E is 26x in the Personal Products industry in Europe.Valuation Update With 7 Day Price Move • May 23Investor sentiment improved over the past weekAfter last week's 22% share price gain to €5.03, the stock trades at a trailing P/E ratio of 29.1x. Average forward P/E is 26x in the Personal Products industry in Europe.お知らせ • May 18Grove, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022Grove, Inc. provided revenue guidance for the fourth quarter of 2022. For the quarter, the company estimated revenue at a range of $16 million to $18 million.Reported Earnings • May 17Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.071 profit in 3Q 2021)Third quarter 2022 results: US$0.003 loss per share (down from US$0.071 profit in 3Q 2021). Revenue: US$10.3m (up 62% from 3Q 2021). Net loss: US$52.7k (down 105% from profit in 3Q 2021). Over the next year, revenue is forecast to grow 96%, compared to a 12% growth forecast for the industry in Germany.Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. CEO & Chairman of the Board Allan Marshall is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • Apr 21Grove, Inc. (NasdaqCM:GRVI) acquired Cygnet Online LLC.Grove, Inc. (NasdaqCM:GRVI) acquired Cygnet Online LLC on April 20, 2022. The acquisitions was made by its brand aggregation division, Upexi. The acquisition was completed with a combination of stock, cash, and debt, resulting in minimal dilution to shareholders. Cygnet has sales over $26,540,000 million in the trailing 12 months. Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of Cygnet Online LLC on April 20, 2022.お知らせ • Apr 13Grove, Inc., Annual General Meeting, May 24, 2022Grove, Inc., Annual General Meeting, May 24, 2022, at 10:00 US Eastern Standard Time. Location: 505 Water Street, Tampa, FL 33602, Tampa Marriot Water Street Florida United States Agenda: To discuss election of directors; to discuss increase in number of shares to stock option; and to discuss ratification of appointment of independent accountants.Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improved over the past weekAfter last week's 18% share price gain to €4.94, the stock trades at a trailing P/E ratio of 22.1x. Average forward P/E is 28x in the Personal Products industry in Europe.Reported Earnings • Feb 15Second quarter 2022 earnings: EPS in line with expectations, revenues disappointSecond quarter 2022 results: EPS: US$0.002 (down from US$0.008 in 2Q 2021). Revenue: US$10.7m (up 156% from 2Q 2021). Net income: US$64.8k (down 37% from 2Q 2021). Profit margin: 0.6% (down from 2.5% in 2Q 2021). Revenue missed analyst estimates by 9.6%. Over the next year, revenue is forecast to grow 45%, compared to a 8.3% growth forecast for the industry in Germany.Valuation Update With 7 Day Price Move • Jan 14Investor sentiment improved over the past weekAfter last week's 17% share price gain to €4.16, the stock trades at a trailing P/E ratio of 17.6x. Average forward P/E is 30x in the Personal Products industry in Europe.Valuation Update With 7 Day Price Move • Dec 08Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €3.66, the stock trades at a trailing P/E ratio of 17.3x. Average forward P/E is 29x in the Personal Products industry in Europe.Board Change • Dec 06High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. President Robb Hackett is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Nov 17First quarter 2022 earnings released: EPS US$0.033 (vs US$0.078 loss in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: US$8.45m (up 188% from 1Q 2021). Net income: US$511.7k (up US$1.32m from 1Q 2021). Profit margin: 6.1% (up from net loss in 1Q 2021).Valuation Update With 7 Day Price Move • Oct 15Investor sentiment improved over the past weekAfter last week's 70% share price gain to €7.20, the stock trades at a trailing P/E ratio of 37.4x. Average forward P/E is 32x in the Personal Products industry in Europe.Reported Earnings • Sep 30Full year 2021 earnings released: EPS US$0.25 (vs US$0.53 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: US$24.1m (up 225% from FY 2020). Net income: US$2.93m (up US$8.31m from FY 2020). Profit margin: 12% (up from net loss in FY 2020).お知らせ • Aug 20Grove, Inc. (NasdaqCM:GRVI) signed a letter of intent to acquire Interactive Offers LLC.Grove, Inc. (NasdaqCM:GRVI) signed a letter of intent to acquire Interactive Offers LLC on August 19, 2021. The contemplated acquisition is subject to completion of due diligence and definitive agreements and is expected to be completed within the next 30 days.お知らせ • Aug 07Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of VitaMedica Corporation.Grove, Inc. (NasdaqCM:GRVI) entered into a non binding letter of intent to acquire VitaMedica Corporation on June 29, 2021. The parties plan to negotiate in good faith a definitive binding agreement over the next 30 days. It is anticipated that if the acquisition does ultimately close, it will be immediately accretive to Grove, being both top line and net income positive for the company. Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of VitaMedica Corporation on August 5, 2021. Barry C. Averitt of Averitt & Alford, P.A. acted as legal advisor to Grove, Inc. Steven E. Burton of Speciale & Burton, APC acted as legal advisor to the sellers.株主還元7TQ0DE Personal ProductsDE 市場7D1.2%0.8%2.4%1Yn/a-11.8%1.2%株主還元を見る業界別リターン: 7TQ0がGerman Personal Products業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: 7TQ0 German市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is 7TQ0's price volatile compared to industry and market?7TQ0 volatility7TQ0 Average Weekly Movement23.2%Personal Products Industry Average Movement5.2%Market Average Movement6.1%10% most volatile stocks in DE Market13.4%10% least volatile stocks in DE Market2.7%安定した株価: 7TQ0の株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 7TQ0の weekly volatility ( 23% ) は過去 1 年間安定していますが、依然としてGermanの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201859Allan Marshallwww.upexi.comブランドオーナーであるUpexi, Inc.は、ペット、外科、回復、皮膚、美容、健康、ウェルネス市場における消費者向け製品の開発、製造、販売に従事している。消費者直販ネットワーク、卸売パートナーシップ、主要サードパーティプラットフォームを通じて製品を販売している。以前はグローブ社として知られていたが、2022年8月にUpexi, Inc.に社名変更した。同社は2018年に法人化され、フロリダ州タンパに本社を置いている。もっと見るUpexi, Inc. 基礎のまとめUpexi の収益と売上を時価総額と比較するとどうか。7TQ0 基礎統計学時価総額€77.26m収益（TTM）-€196.83m売上高(TTM)€22.52m3.4xP/Sレシオ-0.4xPER（株価収益率7TQ0 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計7TQ0 損益計算書（TTM）収益US$26.14m売上原価US$3.39m売上総利益US$22.75mその他の費用US$251.20m収益-US$228.45m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-3.41グロス・マージン87.04%純利益率-874.01%有利子負債／自己資本比率-466.2%7TQ0 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/25 10:20終値2026/05/22 00:00収益2026/03/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Upexi, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Brian KinstlingerAlliance Global PartnersBrett KnoblauchCantor Fitzgerald & Co.Thomas ShinskeCantor Fitzgerald & Co.1 その他のアナリストを表示
Board Change • May 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gene Salkind was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 06+ 1 more updateUpexi, Inc., Annual General Meeting, Jun 15, 2026Upexi, Inc., Annual General Meeting, Jun 15, 2026. Location: at 3030 n. rocky point drive, suite 420, fl 33607, tampa United States
お知らせ • Feb 10Upexi, Inc. has completed a Follow-on Equity Offering in the amount of $7.41429 million.Upexi, Inc. has completed a Follow-on Equity Offering in the amount of $7.41429 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,337,000 Price\Range: $1.17 Discount Per Security: $0.0585 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 6,337,000 Transaction Features: Registered Direct Offering
お知らせ • Feb 06Upexi, Inc. has filed a Follow-on Equity Offering.Upexi, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,337,000 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 6,337,000 Transaction Features: Registered Direct Offering
お知らせ • Feb 05Upexi, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.Upexi, Inc. has filed a Follow-on Equity Offering in the amount of $500 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Jan 31Upexi, Inc. to Report Q2, 2026 Results on Feb 10, 2026Upexi, Inc. announced that they will report Q2, 2026 results on Feb 10, 2026
Board Change • May 21Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gene Salkind was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 06+ 1 more updateUpexi, Inc., Annual General Meeting, Jun 15, 2026Upexi, Inc., Annual General Meeting, Jun 15, 2026. Location: at 3030 n. rocky point drive, suite 420, fl 33607, tampa United States
お知らせ • Feb 10Upexi, Inc. has completed a Follow-on Equity Offering in the amount of $7.41429 million.Upexi, Inc. has completed a Follow-on Equity Offering in the amount of $7.41429 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,337,000 Price\Range: $1.17 Discount Per Security: $0.0585 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 6,337,000 Transaction Features: Registered Direct Offering
お知らせ • Feb 06Upexi, Inc. has filed a Follow-on Equity Offering.Upexi, Inc. has filed a Follow-on Equity Offering. Security Name: Common Stock Security Type: Common Stock Securities Offered: 6,337,000 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 6,337,000 Transaction Features: Registered Direct Offering
お知らせ • Feb 05Upexi, Inc. has filed a Follow-on Equity Offering in the amount of $500 million.Upexi, Inc. has filed a Follow-on Equity Offering in the amount of $500 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: At the Market Offering
お知らせ • Jan 31Upexi, Inc. to Report Q2, 2026 Results on Feb 10, 2026Upexi, Inc. announced that they will report Q2, 2026 results on Feb 10, 2026
お知らせ • Dec 02Upexi, Inc. announced that it has received $10.000001 million in fundingOn December 2, 2025, Upexi, Inc. announced that it has received $ 10,000,000 in funding from issuance of common stock of the company and closed the transaction. The company raised $10,000,000 upfront with up to an additional $ 13,000,000 of aggregate gross proceeds upon the cash exercise in full of warrants of the company which adds up to $ 23,000,000 in proceeds.
お知らせ • Nov 26Upexi, Inc. announced that it expects to receive $10.000001 million in fundingUpexi, Inc. announced that it has entered into a securities purchase agreement with a single institutional investor for issuance of 3,289,474 common shares at a price of $3.04 per share for gross proceeds of $10,000,000.96; and warrants to purchase up to 3,289,474 common shares on November 26, 2025. The warrants will have an exercise price of $4, will be immediately exercisable, and will expire 48 months from issuance. The closing of the offering is expected to occur on or about December 1, 2025, subject to the satisfaction of customary closing conditions.
お知らせ • Nov 14Upexi, Inc. (NasdaqCM:UPXI) announces an Equity Buyback for $50 million worth of its shares.Upexi, Inc. (NasdaqCM:UPXI) announces a share repurchase program. Under the program, the company will repurchase up to $50 million worth of it's shares.
お知らせ • Nov 08Upexi, Inc. to Report Q1, 2026 Results on Nov 11, 2025Upexi, Inc. announced that they will report Q1, 2026 results on Nov 11, 2025
お知らせ • Oct 24Upexi, Inc. Welcomes Jon Najarian to the Upexi Advisory CommitteeUpexi, Inc. announced the addition of Jon Najarian to the Upexi Advisory Committee, joining Arthur Hayes and S?L Big Brain as founding Upexi Advisory Committee members. Jon Najarian is a highly influential figure in the world of finance, renowned for his deep expertise in options trading and market strategy. A former professional football player, Jon co-founded options trading firm Mercury Trading and later launched financial education company Market Rebellion, cementing his reputation as a market heavyweight across both professional and retail trading. He is an inductee into the U.S. Options Industry Council Hall of Fame, having received the Lifetime Contribution Award in recognition of his enduring impact on the industry. Beyond his trading acumen, Jon is a prominent media personality, frequently appearing on Fox Business, NewsMax, NewsNation, and other financial platforms, where his market analyses and actionable insights reach millions of investors. With a combination of professional credibility, entrepreneurial success, and exceptional visibility, Jon has emerged as one of the most recognized and trusted voices for both institutional and retail traders navigating complex markets.
お知らせ • Aug 12Upexi, Inc. Announces Establishment of Advisory CommitteeUpexi, Inc. announced the establishment of the Upexi Advisory Committee, composed of highly prominent individuals from the digital assets and traditional finance industries. Upexi will seek to leverage the expertise, visibility and network of the Advisory Committee by: In conjunction with the establishment of the Advisory Committee, Upexi has welcomed Arthur Hayes (Twitter: @CryptoHayes) as its first member. A former equity derivatives trader at Deutsche Bank and Citigroup, Arthur’s deep financial acumen and bold vision quickly propelled him to the forefront of the digital assets space, where he co-founded BitMEX, one of the world’s largest cryptocurrency exchanges, and revolutionized digital asset trading with the invention of the perpetual swap – the most widely-traded crypto financial product of all time. Arthur is widely regarded as a thought leader whose market insights and macroeconomic commentary are followed closely by investors around the world. His fearless approach to innovation and profound impact on the industry has cemented his legacy as one of the space’s most iconic and respected voices. Additional Advisory Committee members will be announced over the coming weeks, with Committee-related content and initiatives forthcoming over the coming year and beyond. Arthur Hayes is the CIO of Maelstrom, a family office that invests across the crypto ecosystem. He is also the co-founder of BitMEX – the first crypto unicorn. Prior to entering the crypto industry, he worked as a trader in the capital markets divisions of Deutsche Bank and Citibank. Arthur holds a Bachelors of Economics from the Wharton School of Business. He has appeared on major business news networks including Bloomberg and CNBC. He is active on X (@cryptohayes) and releases a monthly newsletter (Crypto Trader Digest) read by thousands of investors globally.
お知らせ • Jul 26Upexi, Inc. announced that it expects to receive $500 million in funding from A.G.P. / Alliance Global Partners Corp.Upexi, Inc announced a private placement and entered into a purchase agreement with A.G.P./Alliance Global Partners to issue common shares for aggregate gross proceeds of $500,000,000 on July 25, 2025. Pursuant to the purchase agreement, the Company shall have the right, but not the obligation, to direct the Investor to purchase the lesser of (i) $500,000,000 or (ii) the Exchange Cap, which shall be the number of shares not to exceed 19.99% of the Company’s shares of common stock, par value $0.00001 per share, outstanding on July 25, 2025, unless the Company’s stockholders have approved the issuance of Common Stock in excess of the Exchange Cap, upon satisfaction of certain terms and conditions contained in the Purchase Agreement, including, but not limited to, an effective registration statement filed with the U.S. Securities and Exchange Commission. The Common Stock will be offered pursuant to the exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) of Regulation D promulgated thereunder, and applicable state securities laws.
お知らせ • Jul 17Upexi, Inc. announced that it has received $199.828744 million in funding from Big Brain HoldingsOn July 17, 2025, Upexi, Inc closed the transaction. The company issued convertible Notes for aggregate gross proceeds of $150,000,000 in its second and final tranche. The transaction included participation from from Big brain Holdings as a lead Investor among other Institutional Investors and qualified purchasers.
お知らせ • Jul 13Upexi, Inc. announced that it expects to receive $49.828744 million in fundingUpexi, Inc. announces that it has entered into securities purchase agreements to issue 12,457,186 shares of common stock at a price of $4 per share for gross proceeds of $49,828,744 on July 11, 2025. The closing of the Equity Offering is expected to occur on or about July 14, 2025.
お知らせ • May 17Upexi, Inc. announced delayed 10-Q filingOn 05/16/2025, Upexi, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 01Upexi, Inc., Annual General Meeting, Jun 16, 2025Upexi, Inc., Annual General Meeting, Jun 16, 2025. Location: 3030 n. rocky point drive, suite 420, florida 33607., tampa, United States
お知らせ • Apr 26Upexi, Inc. announced that it has received $99.99211 million in funding from GSR, Big Brain, White Star Capital, L.P., Delta Blockchain Fund LPOn April 24, 2025, Upexi, Inc. closed the transaction. The company issued 35,970,383 shares of common stock and 7,889,266 pre-funded warrants at a price of $2.28 per share for aggregate gross proceeds of approximately $100 million.
お知らせ • Apr 21Upexi, Inc. announced that it expects to receive $100 million in funding from GSR, Big Brain, White Star Capital, L.P., Delta Blockchain Fund LP and other investorsUpexi, Inc. announced that it has entered into securities purchase agreements with certain investors to issue 43,859,649 shares of common stock or pre-funded warrants at issue price of $2.28 per share for gross proceeds of $99,999,999.72 on April 21, 2025. The transaction includes participation from lead investor, GSR Markets UK Limited, Big Brain, Anagram, Delphi Ventures, White Star Capital, Maelstrom, the family office of Arthur Hayes, Hivemind, Borderless, Morgan Creek, Elune Capital, and Delta Blockchain Fund, including Austin Federa, Frank Chaparro, Joey Krug, Bartosz Lipinski, Larry Wu, and Jordan Prince, among others including Allan Marshall. The closing of the offering is expected to occur on or about April 24, 2025. The offer and sale of the foregoing securities is being made in a private placement in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended and/or Regulation D promulgated thereunder, or applicable state securities laws.
お知らせ • Nov 22Upexi Receives Notice from the Nasdaq Stock MarketUpexi, Inc. received a Non Compliance Letter from The Nasdaq Stock Market LLC due to the Company’s failure to timely file its Form 10-Q Quarterly Report for the period ended September 30, 2024, in violation of Nasdaq Listing Rule 5250(c)(1). The Company failed to timely file due to circumstances beyond its control, and intends to file its Form 10-Q Quarterly Report shortly after it is able to file its Form 10-K Annual Report. Pursuant to the Nasdaq Listing Rules, the Company has until December 20, 2024 to submit a plan to regain compliance. If the plan is accepted, an extension may be granted of up to 180 calendar days from the due date of the Initial Delinquent Filing, or April 14, 2025, to regain compliance. The Notice has no immediate effect on the listing or trading of the Company’s common stock.
お知らせ • Nov 15Upexi, Inc. announced delayed 10-Q filingOn 11/14/2024, Upexi, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 24+ 1 more updateUpexi, Inc. to Report Fiscal Year 2024 Results on Nov 01, 2024Upexi, Inc. announced that they will report fiscal year 2024 results at 9:30 AM, US Eastern Standard Time on Nov 01, 2024
お知らせ • Oct 03Nasdaq Grants Additional 180 Days to Upexi to Regain Compliance with Minimum Bid Price RequirementUpexi, Inc. received a letter from The Nasdaq Stock Market LLC (Nasdaq") indicating that, for thirty consecutive business days prior to the date thereof, the bid price for the Company's common stock (the Common Stock") had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the Minimum Bid Price Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until September 30, 2024, to regain compliance. The Common Stock did not regain compliance with the Minimum Bid Price Requirement within such period. The Company timely requested, and was granted by Nasdaq on October 1, 2024, an additional 180 calendar days to regain compliance with the Minimum Bid Price Requirement.
お知らせ • Oct 01Upexi, Inc. announced delayed annual 10-K filingOn 09/30/2024, Upexi, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
Board Change • Aug 15Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gene Salkind was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 07David Romano, Nick Romano and Eric Limont acquired E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) for $2 million.David Romano, Nick Romano and Eric Limont acquired E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) for $2 million on August 1, 2024. A cash consideration of $2 million will be paid by E-Core Holdings, LLC. The purchase price in the transaction was $2 million. In addition, in connection with the closing of the transaction (i) Upexi, Inc. was released as a guarantor from E-Core, Inc’s commercial loan facility, and (ii) all subordinated promissory notes issued by Upexi, Inc. in connection with the Upexi, Inc.’s initial acquisition of E-Core, Inc were cancelled and any outstanding principal and interest thereunder was deemed paid in full. On the Closing Date, (a) each Transaction Document shall be deemed null and void, and all obligations of the parties thereunder shall terminate; (b) Upexi Newco shall assign and transfer back to Upexi Newcos all of E-Core Newco’s right, title and interest in and to 4,000 shares of common stock of E-Core purchased from Upexi Newco in the Transaction (the “ E-Core Shares ”), constituting all of E-Core’s issued and outstanding securities, free and clear of any liens or encumbrances; and (c) the Consideration shall be paid in full by the Parties. Dickinson Wright PLLC acted as legal advisor to Upexi, Inc. and Korn & Kalish LLP acted as legal advisor to David Romano, Nick Romano and Eric Limont. David Romano, Nick Romano and Eric Limont completed the acquisition of E-Core, Inc from Upexi, Inc. (NasdaqCM:UPXI) on August 1, 2024.
お知らせ • Jun 22Upexi Provides Update on Filing Form 10Q for March 31, 2024Upexi, Inc. (the Company" or Upexi") is providing shareholders with a update on filing its financial statements for the three and nine months ended March 31, 2024. On June 17, 2024, the Company received a notice from Nasdaq Listing Qualifications that since the Company has not yet filed its Form 10-Q for the period ended March 31, 2024 (the Filing"), it no longer complies with our Listing Rules (the Rules") for continued listing. Under the Rules the Company now has 60 calendar days to submit a plan to regain compliance and if we accept your plan, we can grant an exception of up to 180 calendar days from the Filing's due date, or until December 11, 2024, to regain compliance. Upexi management has discussed this with the Nasdaq and expects to file the form 10-Q for the period ended March 31, 2024 prior to the end of June 30, 2024 and once this is filed, a plan will not be necessary to regain compliance. The Nasdaq Notice Letter has no immediate effect on the listing or trading of the Company's common stock.
お知らせ • Jun 21Upexi, Inc. to Report Q3, 2024 Results on Jun 24, 2024Upexi, Inc. announced that they will report Q3, 2024 results on Jun 24, 2024
お知らせ • Jun 18MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC acquired VitaMedica Corporation from Upexi, Inc. (NasdaqCM:UPXI) for $6 million.MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC acquired VitaMedica Corporation from Upexi, Inc. (NasdaqCM:UPXI) for $6 million on June 13, 2024. A cash consideration of $4 million will be paid by MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC. MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC will pay an earnout/contingent payment of $1 million promissory note and of $1 million cash. As part of consideration, $6 million is paid towards common equity of VitaMedica Corporation. MFA Holdings Corp., 1000915944 Ontario Inc and Nutraproducts LLC acquired VitaMedica Corporation from Upexi, Inc. (NasdaqCM:UPXI) for $6 million on June 13, 2024.
お知らせ • May 17Upexi, Inc. announced delayed 10-Q filingOn 05/15/2024, Upexi, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 03Upexi, Inc., Annual General Meeting, Jun 10, 2024Upexi, Inc., Annual General Meeting, Jun 10, 2024, at 09:00 US Eastern Standard Time. Location: 3030 N. Rocky Point Drive, Suite 420 Tampa United States Agenda: To elect five (5) director nominees, nominated by the board of directors, for a one-year term; to ratify the appointment of b f Borgers CPA pc as independent registered public accounting firm for the fiscal year ending June 30, 2024; and to consider such other business.
New Risk • Apr 18New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.30m (US$9.92m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.0m free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Market cap is less than US$10m (€9.30m market cap, or US$9.92m). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$5.6m net loss next year). Shareholders have been diluted in the past year (16% increase in shares outstanding).
お知らせ • Apr 03Upexi Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)On April 1, 2024, Upexi, Inc. (the ‘Company’) received a letter (the ‘Nasdaq Bid Price Letter’) from The Nasdaq Stock Market LLC (‘Nasdaq’) indicating that, for thirty consecutive business days prior to the date thereof, the bid price for the Company’s common stock (the ‘Common Stock’) had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the ‘Minimum Bid Price Requirement’). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until September 30, 2024, to regain compliance (the ‘Compliance Period’). As of the date of this report, the Common Stock has not regained compliance with the Minimum Bid Price Requirement. In the event the Company does not regain compliance within the Compliance Period, the Company may be eligible for additional time. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of the Company’s intention to cure the deficiency during said second compliance period, by effecting a reverse stock split, if necessary. If the Company meets these requirements, Nasdaq will inform the Company that it has been granted an additional 180 calendar days. However, if it appears to Nasdaq that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice that the Common Stock will be subject to delisting. The Nasdaq Bid Price Letter has no immediate effect on the listing or trading of the Common Stock. The Company intends to continue actively monitoring the bid price for its shares of Common Stock between now and the expiration of the Compliance Period and will consider all available options to resolve the deficiency including a reverse stock split, if necessary, with every intention to regain compliance with the Minimum Bid Price Requirement. In the event the Company receives notification from Nasdaq that the Common Stock is subject to delisting, the Company may appeal the Nasdaq staff’s determination before the Nasdaq Hearings Panel (the ‘Panel’). However, there can be no assurance that, in the event of such appeal, the Panel would grant the Company’s request for continued listing.
Reported Earnings • Feb 15Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.17 profit in 2Q 2023)Second quarter 2024 results: US$0.12 loss per share (down from US$0.17 profit in 2Q 2023). Revenue: US$21.8m (down 19% from 2Q 2023). Net loss: US$2.44m (down 182% from profit in 2Q 2023). Revenue is forecast to grow 7.2% p.a. on average during the next 2 years, compared to a 5.4% growth forecast for the Personal Products industry in Europe.
Board Change • Feb 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. Independent Director Gene Salkind was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 15+ 1 more updateUpexi, Inc. Revises Preliminary and Unaudited Financial Guidance for the First Quarter Ended September 30, 2023Upexi, Inc. revised preliminary and unaudited financial guidance for the first quarter ended September 30, 2023. For the year, the company expects Revenue of approximately $27.3 million, an increase of 136% year-over-year and 53.2% sequentially, and above the previously issue revenue guidance range of $26 million to $27 million.
お知らせ • Sep 15Upexi, Inc. Pet Care Brand, Luckytail, Announces Expansion of Product Line to Include All-Natural Dog SupplementsUpexi Inc. announced LuckyTail, its pet brand and leading designer and manufacturer of pet care solutions, is expanding its latest product line with the launch of all-natural dog supplements. The supplement line will be offered via subscription and in batches, delivering the most value for pet owners' health and grooming needs. The line includes six functional formulas to address the most common concerns dog owners have including, hip & joint, calming, flea & tick, probiotic and allergy & immune issues. With a focus on quality ingredients, all chews are all-natural, human-grade, GMP certified, third-party tested and made in the USA. The line features the following all-natural, chewable supplements: Calming chews improve emotional balance, support relaxation, and relieve stress and anxiety for dogs, a perfect complement to LuckyTail's Ultimate Nail Grinder. AllerImmune chews provide immune-boosting properties and relief from common dog allergy symptoms, including decreased paw licking, itching, flea & tick, and skin irritation. Flea & tick chews are an all-natural, chemical-free solution to help prevent pesky pests.ip & Joint chews promote healthier bones and joints, increased mobility, and reduce soreness and discomfort. As dogs age, their hips and joints can cause pain and discomfort. Probiotic chews provide a safe and effective way to improve pet gut health and reduce bloating, from immune support to gut and digestive health. Skin & Coat chews give dogs a beautiful shiny coat and healthy skin. These dog coat supplements help relieve itching, improve moisturizer, and boost immunity. This launch marks the first of many product expansions LuckyTail has planned, as the brand solidifies its position as a top source to connect pet parents with their pet care needs.
お知らせ • Sep 08Amplifyir Inc. acquired 100% stake in Interactive Offers LLC from Upexi, Inc. (NasdaqCM:UPXI) for $1.25 million.Amplifyir Inc. entered into an equity interest purchase agreement to acquire 100% stake in Interactive Offers LLC from Upexi, Inc. (NasdaqCM:UPXI) for $1.25 million on August 31, 2023. In addition, there is an obligation to pay Upexi 2.5% of certain advertising revenues of Interactive for a two-year period post-closing. Peter Campitiello of McCarter & English acted as legal advisor to Interactive Offers LLC. Ross Carmel of Carmel, Milazzo & Feil LLP acted as legal advisor to Amplifyir.Amplifyir Inc. completed the acquisition of 100% stake in Interactive Offers LLC from Upexi, Inc. (NasdaqCM:UPXI) on August 31, 2023.
New Risk • Aug 07New major risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (€39.5m market cap, or US$43.5m).
お知らせ • May 19Upexi, Inc., Annual General Meeting, Jun 26, 2023Upexi, Inc., Annual General Meeting, Jun 26, 2023, at 10:00 Eastern Daylight. Location: 17129 US Hwy 19 N Clearwater Florida United States Agenda: To elect five (5) director nominees, nominated by the board of directors, for a one-year term, such term to continue until the annual meeting of shareholders in 2024 or until such director's successors are duly elected and qualified or until their earlier resignation or removal; to ratify the appointment of b f Borgers CPA pc as independent registered public accounting firm for the fiscal year ending June 30, 2023; and to consider such other business.
Reported Earnings • May 16Third quarter 2023 earnings released: US$0.11 loss per share (vs US$0.003 loss in 3Q 2022)Third quarter 2023 results: US$0.11 loss per share (further deteriorated from US$0.003 loss in 3Q 2022). Revenue: US$24.2m (up 136% from 3Q 2022). Net loss: US$1.93m (loss widened US$1.88m from 3Q 2022). Revenue is forecast to grow 19% p.a. on average during the next 2 years, compared to a 5.3% growth forecast for the Personal Products industry in Europe.
お知らせ • Feb 16Upexi, Inc. announced delayed 10-Q filingOn 02/15/2023, Upexi, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Reported Earnings • Feb 16Second quarter 2023 earnings released: EPS: US$0.17 (vs US$0.004 in 2Q 2022)Second quarter 2023 results: EPS: US$0.17 (up from US$0.004 in 2Q 2022). Revenue: US$27.1m (up 154% from 2Q 2022). Net income: US$2.96m (up US$2.90m from 2Q 2022). Profit margin: 11% (up from 0.6% in 2Q 2022). Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 5.0% growth forecast for the Personal Products industry in Europe.
Recent Insider Transactions • Dec 06CEO, President & Chairman of the Board recently bought €70k worth of stockOn the 1st of December, Allan Marshall bought around 18k shares on-market at roughly €3.77 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Allan's only on-market trade for the last 12 months.
Reported Earnings • Nov 17First quarter 2023 earnings released: US$0.15 loss per share (vs US$0.033 profit in 1Q 2022)First quarter 2023 results: US$0.15 loss per share (down from US$0.033 profit in 1Q 2022). Revenue: US$11.6m (up 37% from 1Q 2022). Net loss: US$2.55m (down US$3.06m from profit in 1Q 2022). Revenue is forecast to grow 35% p.a. on average during the next 2 years, compared to a 5.7% growth forecast for the Personal Products industry in Europe.
Board Change • Nov 16High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. CEO, President & Chairman of the Board Allan Marshall is the most experienced director on the board, commencing their role in 2019. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 03Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of E-Core, Inc.Grove, Inc. (NasdaqCM:GRVI) signed a non-binding Letter of Intent to acquire E-Core, Inc on August 2, 2022. E- Core was acquired through Upexi. Grove plans to fund this acquisition without an additional equity offering. Grove and E-Core anticipate that the transaction will close in August 2022. Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of E-Core, Inc on November 2, 202. Upexi Inc. will pay consideration in combination of cash, stock and one-to-three year notes.
お知らせ • Oct 28+ 1 more updateBloomios, Inc. (OTCPK:BLMS) acquired Infusionz, LLC from Upexi, Inc. (NasdaqCM:UPXI) for $23.5 million.Bloomios, Inc. (OTCPK:BLMS) acquired Infusionz, LLC from Upexi, Inc. (NasdaqCM:UPXI) for $23.5 million on October 27, 2022. The total purchase consideration of approximately $23.5 million consisted of cash consideration of $5.5 million and $18 million of non-cash consideration. The non-cash consideration consisted of the issuance by Bloomios to Upexi of a $4.5 million senior secured convertible debenture, a $5 million secured subordinated promissory note, and shares of a newly created Series D Convertible Preferred Stock with a value of $8.5 million. The acquisition was funded in part through a senior secured convertible debenture offering with an aggregate principal amount of approximately $13,893,059 (including a 15% original issue discount) led by institutional investors. The total new investment received in connection with the senior secured convertible debenture offering was $6.25 million with the balance of the principal amount consisting of issuances to Upexi and the refinancing of previous loans. Revere Securities LLC and Spartan Capital Securities, LLC acted financial advisors to Bloomios, Inc. Bloomios, Inc. (OTCPK:BLMS) completed the acquisition of Infusionz, LLC from Upexi, Inc. (NasdaqCM:UPXI) on October 27, 2022.
お知らせ • Oct 12Upexi, Inc. Files Patent for its Single Click-to-optin TechnologyUpexi Inc. announced that its SaaS Ad Tech Division, Interactive Offers, has filed a patent for its single click-to-optin technology that has fueled growth and partnerships with large publishers. The competitive landscape and higher advertising costs have forced companies to lower budgets and/or try and find new opportunities. Interactive Offers' unique technology adds value for companies by changing the way advertisers pay for leads. With this new single click-to-optin technology, advertisers will no longer be paying per click or per impression, but will be bidding on a verified lead that has opted in to receive promotions and emails for each advertiser(s).
お知らせ • Sep 30Upexi, Inc. Provides Revenue Guidance for the Fiscal Year 2023Upexi, Inc. provided revenue guidance for the Fiscal year 2023. For the period, the company estimates baseline annual revenue to be in the range of $72 to $82 million for the full fiscal year.
Reported Earnings • Sep 29Full year 2022 earnings released: US$0.13 loss per share (vs US$0.25 profit in FY 2021)Full year 2022 results: US$0.13 loss per share (down from US$0.25 profit in FY 2021). Revenue: US$44.6m (up 85% from FY 2021). Net loss: US$2.10m (down 172% from profit in FY 2021). Revenue is forecast to grow 46% p.a. on average during the next 2 years, compared to a 5.6% growth forecast for the Personal Products industry in Europe.
お知らせ • Sep 01Upexi, Inc. Appoints Anthony Bazan as Chief Operating OfficerOn August 29, 2022, Upexi, Inc. appointed Anthony Bazan as Chief Operating Officer of the Company. Mr. Bazan, age 57, joined the Company in August of 2022 as the Chief Operations Officer. Prior to joining the Company Mr. Bazan was CEO and Director of OnlineTech Stores and Group CEO and Director for Imaging Supplies Consolidation II, a Blackford Capital portfolio group. Mr. Bazan has a 30 year career in operations starting at Rockwell International, Easton Sports, Fiskars, Black & Decker, Jakks Pacific, Mega Brands, and TM International. At Mega Brands, Mr. Bazan was COO from 2008 to 2011. During his tenure Mega Brands grew $200 million in revenue and increased share price from $0.45 to $9.75. At TM International, Mr. Bazan served as CEO and Director from 2017 to 2021. During this period, Mr. Bazan was able to turn around a failing promotional products and e-commerce company, even during the height of COVID-19 when no promotional events were taking place. Mr. Bazan attended the Air Force Academy after earning both a Congressional and Senatorial nomination. A spinal injury caused him to depart the AFA early and honorably, while earning a Certificate of Completion in Engineering. Mr. Bazan continued his education gaining a BA in Economics from California State University of Northridge.
Valuation Update With 7 Day Price Move • Aug 18Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to €4.66, the stock trades at a trailing P/E ratio of 24.2x. Average forward P/E is 25x in the Personal Products industry in Europe. Total loss to shareholders of 18% over the past year.
お知らせ • Aug 03Grove, Inc. (NasdaqCM:GRVI) signed a non-binding LOI to acquire E-Core, Inc.Grove, Inc. (NasdaqCM:GRVI) signed a non-binding LOI to acquire E-Core, Inc on August 2, 2022. E- Core was acquired through Upexi. Grove plans to fund this acquisition without an additional equity offering. The deal uses debt, restricted equity, and payouts in subsequent years based on revenue and EBITDA milestones. Grove and E-Core anticipate that the transaction will close in August 2022.
Valuation Update With 7 Day Price Move • Aug 02Investor sentiment improved over the past weekAfter last week's 18% share price gain to €4.86, the stock trades at a trailing P/E ratio of 26.6x. Average forward P/E is 27x in the Personal Products industry in Europe. Total returns to shareholders of 14% over the past year.
Valuation Update With 7 Day Price Move • Jul 12Investor sentiment improved over the past weekAfter last week's 21% share price gain to €4.51, the stock trades at a trailing P/E ratio of 23.3x. Average forward P/E is 27x in the Personal Products industry in Europe. Negligible returns to shareholders over past year.
お知らせ • Jun 26Grove, Inc.(NasdaqCM:GRVI) dropped from Russell Microcap Value IndexGrove, Inc.(NasdaqCM:GRVI) dropped from Russell Microcap Value Index
Valuation Update With 7 Day Price Move • Jun 14Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €3.92, the stock trades at a trailing P/E ratio of 21.7x. Average forward P/E is 26x in the Personal Products industry in Europe.
Valuation Update With 7 Day Price Move • May 23Investor sentiment improved over the past weekAfter last week's 22% share price gain to €5.03, the stock trades at a trailing P/E ratio of 29.1x. Average forward P/E is 26x in the Personal Products industry in Europe.
お知らせ • May 18Grove, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022Grove, Inc. provided revenue guidance for the fourth quarter of 2022. For the quarter, the company estimated revenue at a range of $16 million to $18 million.
Reported Earnings • May 17Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.071 profit in 3Q 2021)Third quarter 2022 results: US$0.003 loss per share (down from US$0.071 profit in 3Q 2021). Revenue: US$10.3m (up 62% from 3Q 2021). Net loss: US$52.7k (down 105% from profit in 3Q 2021). Over the next year, revenue is forecast to grow 96%, compared to a 12% growth forecast for the industry in Germany.
Board Change • Apr 27High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. CEO & Chairman of the Board Allan Marshall is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • Apr 21Grove, Inc. (NasdaqCM:GRVI) acquired Cygnet Online LLC.Grove, Inc. (NasdaqCM:GRVI) acquired Cygnet Online LLC on April 20, 2022. The acquisitions was made by its brand aggregation division, Upexi. The acquisition was completed with a combination of stock, cash, and debt, resulting in minimal dilution to shareholders. Cygnet has sales over $26,540,000 million in the trailing 12 months. Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of Cygnet Online LLC on April 20, 2022.
お知らせ • Apr 13Grove, Inc., Annual General Meeting, May 24, 2022Grove, Inc., Annual General Meeting, May 24, 2022, at 10:00 US Eastern Standard Time. Location: 505 Water Street, Tampa, FL 33602, Tampa Marriot Water Street Florida United States Agenda: To discuss election of directors; to discuss increase in number of shares to stock option; and to discuss ratification of appointment of independent accountants.
Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improved over the past weekAfter last week's 18% share price gain to €4.94, the stock trades at a trailing P/E ratio of 22.1x. Average forward P/E is 28x in the Personal Products industry in Europe.
Reported Earnings • Feb 15Second quarter 2022 earnings: EPS in line with expectations, revenues disappointSecond quarter 2022 results: EPS: US$0.002 (down from US$0.008 in 2Q 2021). Revenue: US$10.7m (up 156% from 2Q 2021). Net income: US$64.8k (down 37% from 2Q 2021). Profit margin: 0.6% (down from 2.5% in 2Q 2021). Revenue missed analyst estimates by 9.6%. Over the next year, revenue is forecast to grow 45%, compared to a 8.3% growth forecast for the industry in Germany.
Valuation Update With 7 Day Price Move • Jan 14Investor sentiment improved over the past weekAfter last week's 17% share price gain to €4.16, the stock trades at a trailing P/E ratio of 17.6x. Average forward P/E is 30x in the Personal Products industry in Europe.
Valuation Update With 7 Day Price Move • Dec 08Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to €3.66, the stock trades at a trailing P/E ratio of 17.3x. Average forward P/E is 29x in the Personal Products industry in Europe.
Board Change • Dec 06High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. President Robb Hackett is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Nov 17First quarter 2022 earnings released: EPS US$0.033 (vs US$0.078 loss in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: US$8.45m (up 188% from 1Q 2021). Net income: US$511.7k (up US$1.32m from 1Q 2021). Profit margin: 6.1% (up from net loss in 1Q 2021).
Valuation Update With 7 Day Price Move • Oct 15Investor sentiment improved over the past weekAfter last week's 70% share price gain to €7.20, the stock trades at a trailing P/E ratio of 37.4x. Average forward P/E is 32x in the Personal Products industry in Europe.
Reported Earnings • Sep 30Full year 2021 earnings released: EPS US$0.25 (vs US$0.53 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: US$24.1m (up 225% from FY 2020). Net income: US$2.93m (up US$8.31m from FY 2020). Profit margin: 12% (up from net loss in FY 2020).
お知らせ • Aug 20Grove, Inc. (NasdaqCM:GRVI) signed a letter of intent to acquire Interactive Offers LLC.Grove, Inc. (NasdaqCM:GRVI) signed a letter of intent to acquire Interactive Offers LLC on August 19, 2021. The contemplated acquisition is subject to completion of due diligence and definitive agreements and is expected to be completed within the next 30 days.
お知らせ • Aug 07Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of VitaMedica Corporation.Grove, Inc. (NasdaqCM:GRVI) entered into a non binding letter of intent to acquire VitaMedica Corporation on June 29, 2021. The parties plan to negotiate in good faith a definitive binding agreement over the next 30 days. It is anticipated that if the acquisition does ultimately close, it will be immediately accretive to Grove, being both top line and net income positive for the company. Grove, Inc. (NasdaqCM:GRVI) completed the acquisition of VitaMedica Corporation on August 5, 2021. Barry C. Averitt of Averitt & Alford, P.A. acted as legal advisor to Grove, Inc. Steven E. Burton of Speciale & Burton, APC acted as legal advisor to the sellers.
